Antioestrogen-mediated cell cycle arrest and apoptosis induction in breast cancer and multiple myeloma cells

in Journal of Molecular Endocrinology

Antioestrogens (AEs) are synthetic molecules that block proliferation and induce apoptosis in breast cancer (BC) cells, principally by competing with oestradiol for binding to oestrogen receptors. Their antiproliferative activity and their pro-apoptotic capacity are well documented and a small number of molecules of this class are currently used clinically for the treatment of BC. AEs also inhibit cell cycle progression and/or induce apoptosis in multiple myeloma (MM) cells. Encouraging preliminary results have been obtained with patients and on xenografts with MM, providing a rational basis for the clinical use of AEs. This review focuses on antioestrogen-mediated signalling for blocking targets involved in the cell cycle, survival and apoptosis in both BC and MM cells. Improvement in our understanding of the mechanisms underlying the relationships between these compounds and their targets should lead to more beneficial therapeutic strategies.

Abstract

Antioestrogens (AEs) are synthetic molecules that block proliferation and induce apoptosis in breast cancer (BC) cells, principally by competing with oestradiol for binding to oestrogen receptors. Their antiproliferative activity and their pro-apoptotic capacity are well documented and a small number of molecules of this class are currently used clinically for the treatment of BC. AEs also inhibit cell cycle progression and/or induce apoptosis in multiple myeloma (MM) cells. Encouraging preliminary results have been obtained with patients and on xenografts with MM, providing a rational basis for the clinical use of AEs. This review focuses on antioestrogen-mediated signalling for blocking targets involved in the cell cycle, survival and apoptosis in both BC and MM cells. Improvement in our understanding of the mechanisms underlying the relationships between these compounds and their targets should lead to more beneficial therapeutic strategies.

Keywords:

Introduction

The development of hormonal treatments has led to an extensive search for highly effective and well-tolerated molecules. Antioestrogens (AEs; Fig. 1) are synthetic compounds entirely fulfilling these criteria. They inhibit the activation of two different but related ligand-induced transcription factors of the nuclear receptor superfamily: the oestrogen receptors (ERα; Green et al. 1988) and ERβ (Kuiper et al. 1996, Mosselman et al. 1996). ERα is the master regulator of breast cancer (BC) tumour behaviour and is much more strongly expressed in BC tumours than ERβ (Dahlman-Wright et al. 2006). It is currently thought that ERβ represses growth by inhibiting ERα-mediated transcriptional activity (Hall & McDonnell 1999, Liu et al. 2002, Lindberg et al. 2003, Faulds et al. 2004, Strom et al. 2004), and the balance between the levels of ER subtypes appears as an important regulator of the mitogenic activity of 17 beta oestradiol (E2; Matthews et al. 2006, Holst et al. 2007). AEs block the binding of E2 to ERα and inhibit the E2-induced effects mediated by the two ERs. However, this model cannot account for all the effects of AEs. Indeed, it has been shown that some ERα receptors are located in the cancer cell membrane, facilitating E2- and DNA-independent ER activation through crosstalk with the growth factor-induced activation of cell-surface tyrosine kinase receptors (Moss et al. 1997, Falkenstein et al. 2000, Hanstein et al. 2004). Thus, two different types of signalling may be mediated by E2, with nuclear (genomic) and extra-nuclear (non-genomic) effects (for reviews see (O'Malley 2005, Song et al. 2006)).

Figure 1
Figure 1

Chemical structures of antioestrogens. 4-hydroxy-tamoxifen (4-HT), the active metabolite of tamoxifen and raloxifen belong to the selective oestrogen receptor modulator (SERMs) family. The members of this family act either as E2-agonists or -antagonists depending on ER subtype and cell context. ICI 182 780 and RU58668 are selective oestrogen receptor down-regulators (SERDs), acting as pure antioestrogens.

Citation: Journal of Molecular Endocrinology 40, 3; 10.1677/JME-07-0143

The ERβ subtype has been identified not only in the mammary gland and both male and female reproductive tissues, but also in the colon, brain, pancreas and haematopoietic cells of the myeloid and lymphoid lineages (Enmark & Gustafsson 1999, Shim et al. 2003). Several groups have shown that AEs block proliferation and induce apoptosis in multiple myeloma (MM) cells, as in BC cells (Treon et al. 1998, Otsuki et al. 2000, Gauduchon et al. 2005, Olivier et al. 2006). In recent years, we have focused on deciphering the molecular mechanisms by which AEs, both selective oestrogen receptor modulators (SERMs), such as 4-hydroxy-tamoxifen (4-HT), and selective oestrogen receptor down-regulators (SERDs), such as ICI 182 780 (ICI or Faslodex®) and RU58668 (RU), arrest the cell cycle and/or induce apoptosis in hormone-dependent BC and MM cells. We provide here a review of some of our data. Despite the use of different molecular partners, the signalling pathways involved in cell cycle arrest and the induction of apoptosis by these AEs are similar regardless of the type of cancer cell considered.

Oestrogens and antioestrogen effects in mammary gland cells

Growth and anti-apoptotic properties of oestrogens

ERs are the predominant target of E2 in the mammary gland. We will not describe the mechanism of action of these transcription factors in detail here, because many reviews have covered the latest discoveries concerning nuclear and membrane ER activities and clinical studies (Osborne & Schiff 2005, Heldring et al. 2007, Jordan & Brodie 2007, Lonard & O'Malley 2007, Popov et al. 2007). In the mammary gland, E2 promotes cell proliferation in both normal and transformed epithelial cells by modifying the expression of hormone-responsive genes involved in the cell cycle and/or programmed cell death. In ER-positive human BC MCF-7 cells, the principal action of E2 is the induction of proliferation through the stimulation of G1- to S-phase transition. This induction is associated with the rapid and direct up-regulation of c-myc, which controls cyclin D1 expression, the activation of cyclin-dependent kinase (Cdk) and the phosphorylation of retinoblastoma protein (pRb; Fig. 2; Altucci et al. 1996, Foster & Wimalasena 1996, Hurd et al. 1997, Prall et al. 1997, Doisneau-Sixou et al. 2003). Evidence for a key role of c-myc in E2 action has been obtained from experiments showing that antisense oligonucleotides inhibit E2 stimulated BC cell proliferation (Watson et al. 1991) and that the induction of c-Myc in AE-arrested cells can mimic the effects of E2 by reinitiating cell cycle progression (Prall et al. 1998). The mitogenic and anti-apoptotic activities of E2 are combined through the activation of bcl-2 gene expression and the production of smaller amounts of p53 and caspase-3 in primary cultures of normal mammary epithelial cells (Somai et al. 2003). Moreover, E2/ERα complexes bind directly to a cAMP-response element and a more distal Sp1 site on the cyclin D1 promoter, leading to an increase in cyclin D1 mRNA levels (Altucci et al. 1996, Prall et al. 1997, Sabbah et al. 1999, Castro-Rivera et al. 2001). ERβ competes with ERα in the induction of cyclin D1 transcription (Liu et al. 2002).

Figure 2
Figure 2

Schematic illustration of the activities of oestradiol and antioestrogens in MCF-7 cells. Following E2 treatment, a rapid transcription-mediated increase in c-myc expression occurs, facilitating cyclin E–Cdk2 activation and entry into S phase. Concomitantly, E2 down-regulates p21Cip1 and p27Kip1 and increases cyclin D1 levels. The formation of complexes containing Cdk4 and sequestrating Ckis is enhanced. Ckis levels are down-regulated upon c-myc expression. All these events initiate the phosphorylation of pRb. Cyclin D1 in bold typeface: increase in cyclin D1 levels with activated cyclin–Cdk complexes; *increase in Cdk activity. In grey boxes, low levels of Cki. In black, E2-mediated effects. In red, AE-mediated inhibition leading to cell cycle arrest in G0/G1. Refer to text for details and references.

Citation: Journal of Molecular Endocrinology 40, 3; 10.1677/JME-07-0143

E2 also rapidly activates cyclin E–Cdk2 complexes and, by relieving the inhibition mediated by the natural Cdk inhibitor (Cki) p21Cip1, accelerates the G1 to S transition (Foster & Wimalasena 1996, Planas-Silva & Weinberg 1997, Prall et al. 1997, 2001). Another key element of the regulatory apparatus of the G1 phase is Cki p27Kip1, which inhibits both Cdk2 activity in G0 and early G1 and acts as an assembly factor for cyclin D–Cdk4/6 complexes in early G1 (see Sherr & Roberts 1999, for a review). The functional expression of p27Kip1 is essential for normal proliferative responses in the mammary epithelium (Muraoka et al. 2001). E2 activates cyclin E–Cdk2 complexes in MCF-7 cells, and the G1–S transition is associated with a decrease in the levels and activities of p27Kip1 and p21Cip1 (Foster & Wimalasena 1996, Prall et al. 1997, Foster et al. 2001; Fig. 2). Moreover, E2 up-regulates Bcl-2 protein levels in MCF-7, T47-D and ZR-75-1 BC cells (Gompel et al. 2000).

Growth inhibition of AEs

The growth-inhibiting effects of AEs in ER-positive BC cells and normal epithelial mammalian cells result from cell cycle arrest in the G0/G1 phase (Musgrove et al. 1993, Doisneau-Sixou et al. 2003, Somai et al. 2003, Jamerson et al. 2004). This antiproliferative activity is associated with the inhibition of Cdk activity and a decrease in pRb phosphorylation (Watts et al. 1995). In addition to the cell cycle regulator c-Myc (Jamerson et al. 2004), AEs target cyclin D1, cyclin E, p21Cip1 and p27Kip1 (Caldon et al. 2006). Both Cki molecules are weakly expressed in mammary cells, such as BC cells, but exposure to 4-HT, ICI or RU strongly increases their expression (Cariou et al. 2000, Slingerland & Pagano 2000, Foster et al. 2003). Inhibition of the expression of either p21Cip1 or p27Kip1 with antisense oligonucleotides maintains Cdk2 in an active state and prevents AE-mediated G1 blockade (Cariou et al. 2000, Carroll et al. 2000). AEs from different classes have different effects on ERα-positive BC cells: 4-HT blocks these cells in the G1 phase, whereas ICI and RU render these cells quiescent (Carroll et al. 2000, 2003; Fig. 2).

Pro-apoptotic activity of AEs

Mitochondria are known to play an integral role in apoptosis, and it was demonstrated that tamoxifen (Tam) induces increased rate of apoptosis after long-term treatment (Thiantanawat et al. 2003). Caspase-3 and caspase-7 are the most commonly studied effector caspases. When activated, they directly target proteins involved in cell integrity and are responsible for the final stage of cell death (Strasser et al. 2000). Specific caspase activation cascades are dependent on apoptotic stimuli (Riggins et al. 2005a). T47-D and ZR-75-1 cells contain caspase-3 that is absent from MCF-7 cells (Janicke et al. 1998). In MCF-7 cells, apoptosis proceeds via the sequential activation of caspase-7 and caspase-6 (Table 1). However, Tam increases the activity of caspases-3 in ER-negative BC cells (Mandlekar et al. 2000) and of caspase-9, caspase-6 and caspase-7 in MCF-7 cells (Thiantanawat et al. 2003) with concomitant down-regulation of Bcl-2 and up-regulation of Bax. In T47-D cells, Tam treatment activates caspase-3 (Ellis et al. 2003). It was also shown that in MCF-7 cells and rat mammary tumours, well known to resemble human BC tumours, Tam causes activation of caspase-8, a caspase normally related to membrane death receptor activation (Mandlekar et al. 2000). Indeed, caspase inhibitor z-VAD-fmk completely blocks Tam-induced apoptosis (Mandlekar et al. 2000). Although intriguing, these data suggest that AEs may affect both intrinsic (via caspase-9 activation) and extrinsic (via caspase-8 activation) apoptotic pathways.

Table 1

Comparison of the apoptotic effects of selective oestrogen receptor modulators (SERMs) and selective oestrogen receptor down-regulators (SERDs) in breast cancer and multiple myeloma cells

BC cellsMM cells
MCF-7T47-DRPMI 8226LP-1
4-HTRU4-HTRU4-HTRU4-HTRU
Death ligand/receptor
 TNF/TNFRNDNDNDNDNDND
 TRAIL/DR4/5NDNDNDND→ (a)→ (a)
 FasL/Fas↗ (a)↗ (a)→ (a)→ (a)
Bcl-2 family
 Bcl-2↘ (b)
 Bcl-XLNDNDNDND→ (a)→ (a)
 Bax→ (a)→ (a)→ (a)→ (a)→ (a)→ (a)
 Bik→ (a)↗ (b)NDNDNDNDNDND
 Mcl-1→ (a) (b)ND (b)ND↘ (a)
Caspase
 Caspase-3abab↗ (a)
 Caspase-4NDNDNDNDNDND
 Caspase-7NDNDNDNDNDND
 Caspase-8NDNDND
 Caspase-9NDNDND

↗, enhanced or activated for caspase; ↘, decreased; →, identical; , cleaved; ND, not determined; (a), our unpublished results; (b), obtained with ICI; ab, absent.

Both SERMs like Tam and SERDs like ICI and RU induce moderate apoptosis in MCF-7 cells (Kandouz et al. 1999, Gompel et al. 2000) accompanied by poly-(ADP-ribose) polymerase (PARP) cleavage. These apoptotic properties are observed at micromolar concentrations of AEs in all BC cells, whereas cell cycle blockade occurs at nanomolar concentrations of AEs, suggesting that these two processes are independent and triggered by separated pathways. It was recently shown that micromolar concentrations of ICI, 4-HT and raloxifen but also E2 induce cell death due to the formation of reactive oxygen species (ROS), triggering classical caspase-dependent apoptosis (Mandlekar et al. 2000, Obrero et al. 2002, Kallio et al. 2005). Tam-induced production of ROS associated with release mitochondrial cytochrome c appears responsible for the early apoptotic effects of Tam. In addition, Tam-induced rapid death of MCF-7 cells is mediated by extracellular signal-regulated kinase signalling that can be abrogated by E2 but not by ICI in an ER-independent mechanism (Zheng et al. 2007). E2-induced apoptosis also occurs in BC cells resistant to long-term oestrogen deprivation (aromatase inhibitors) and to AEs (Gottardis et al. 1988, Lewis et al. 2005) and E2 treatment may constitute a new clinical strategy following exhaustive antihormone therapy (Jordan et al. 2005).

The E2-responsive cell lines MCF-7, T47-D and ZR75.1 all express the surface tumour necrosis factor (TNF), TRAIL and Fas-L receptors, the key mediators of the extrinsic apoptotic pathway the ligand-dependent activation of which generally results in rapid cell death. Unlike E2, Tam up-regulates Fas-L expression (Nagarkatti & Davis 2003). However, in MCF-7 cells subjected to long periods of E2 deprivation, E2-induced apoptosis is correlated with Fas-L expression (Song & Santen 2003). TNF-mediated apoptosis in MCF-7 cells can be abolished by E2 treatment, via an increase in production of the anti-apoptotic mediator Bcl-2 (Burow et al. 2001). Both ICI and Tam enhance TNF-induced cell death, by triggering TNF receptor production and expression at the cell surface (Smolnikar et al. 2000). Thus, significant crosstalk occurs between the TNF- and AE-induced apoptosis pathways (Table 1).

Contradictory data have been published regarding the effects of AEs on the members of the Bcl-2 family. E2 has been shown to up-regulate the anti-apoptotic Bcl-2 protein in oestrogen-dependent BC cells (Gompel et al. 2000), an effect counteracted by both Tam and pure AEs (Kandouz et al. 1999, Zhang et al. 1999, Ameller et al. 2003, Somai et al. 2003, Thiantanawat et al. 2003). In MCF-7 cells, E2 has been shown to decrease levels of the pro-apoptotic Bak protein, whereas aromatase inhibitors or AEs have been shown to increase Bak levels (Leung et al. 1998, Thiantanawat et al. 2003). However, other studies have reported no effects of oestrogens or AEs on levels of Bax or Bak protein (Kandouz et al. 1999, Zhang et al. 1999, Gompel et al. 2000). There is therefore no clear consensus concerning the roles of these molecules in AE-mediated apoptosis. Bcl-XL is produced in small amounts, unaffected by AEs in BC cells. The pro-apoptotic protein Bik is down-regulated by E2 and up-regulated by ICI, but not by the SERMs 4-HT and raloxifen (Frasor et al. 2003, Hur et al. 2004, Frasor et al. 2006).

Thus, in BC cells, the pro-apoptotic activity of AEs is triggered through multiple pathways that are whether dependent or independent on ER signalling.

p53

The tumour suppressor p53 is inactivated in 30% of all BCs. Together with p63 and p73, two other proteins from the same family, p53 is a global regulator of cell cycle checkpoints and apoptosis. MCF-7 and ZR.75.1 cells contain wild-type p53, whereas T47-D cells produce a mutated form unable to bind DNA. As p53-regulated target genes, such as those encoding p21Cip1 and the pro-apoptotic Bax protein, are activated in response to various stimuli, and since ERα binds directly to p53 (Liu et al. 2006, Sayeed et al. 2007), it was suggested that p53 is involved in the response to AEs in BC cells. However, the effects of AEs on p53 remain unclear. It has been reported that the depletion of Tam and E2 decreases p53 levels and that Faslodex can reverse the E2-mediated increase in p53 levels in T-47D cells (Dinda et al. 2002). The group responsible for this study also showed that E2 and Tam induce the transcriptional activity of the P1 promoter of p53 in MCF-7 cells, whereas Faslodex does not (Hurd et al. 1997). These data contrast with data from other studies reporting no change in p53 levels in response to Tam, despite the significant induction of apoptosis and pRb dephosphorylation (Fattman et al. 1998, Zhang et al. 1999). These differences may be due to the subcellular distribution of p53 within cells (Molinari et al. 2000, Lilling et al. 2002). Furthermore, the product of the Mdm2 oncogene, which is overexpressed in various cancers, and encodes an E3 ubiquitin ligase, regulates the stability of ERα by forming a ternary complex with p53 (Duong et al. 2007). In turn, p53 and Mdm2 regulate the E2-dependent down-regulation of ERα and, probably, susceptibility to AE (Duong et al. 2007). Indeed, since ERα inhibits p53-mediated transcriptional repression (Sayeed et al. 2007), it can be emphasised that AE induces apoptosis in BC cells by, at least in part, relieving the inhibitory activity of ERα on p53 activity.

Survival proteins

The deregulation and inappropriate activation of phosphoinositol-3-kinase (PI3K) signalling and its downstream targets, Akt and nuclear factor-κB (NF-κB) have been linked to cancers (Luo et al. 2003). The transcriptional activity of ERα is activated by constitutively activated Akt independently on the presence of E2 but in a PI3K-dependent manner since the PI3K inhibitor wortmanin inhibits both phosphorylation (Ser-167) and activation of ERα (Sun et al. 2001). Such activity is abolished by ICI but not completely by Tam, implicating that Akt-activated ERα contributes to Tam resistance (Michalides et al. 2004, Riggins et al. 2005a,b). Moreover, the p85 subunit of PI3K binds to E2-free ERα (Sun et al. 2001) and the overexpression of Akt protects against Tam-induced apoptosis (Campbell et al. 2001). However, the role of Akt in BC cells is still unclear: for example, in MCF-7 and MDA-MB-231 cells, E2 induces PI3K/Akt activity via an ER-independent signalling pathway that is not affected by AEs (Tsai et al. 2001). However, Akt must be considered as a target of choice in BC therapy since its suppression prevents endocrine therapy resistance (Glaros et al. 2006).

The NF-κB family of transcription factors controls various aspects of the immune system. Among the NF-κB proteins, some possess a Rel homology domain (RHD), such as RelA (also named p65), cRel and RelB, whereas others such as the p105/p50 and the p100/p52 do not. They form hetero-complex proteins by associating with inhibitors (IκB) of NF-κB, which bind to and inhibit DNA binding of the RHDs (Hayden & Ghosh 2004). These complexes are activated through the activation of an externally activated IκB kinase that phosphorylates IκB, leading to its proteasome-mediated degradation and enabling NF-κB-mediated transcription following nuclear translocation. As shown previously, NF-κB binds ER (Ray et al. 1994) and ER inhibits NF-κB pathway by interacting at various steps of the activation cascade (see Kalaitzidis & Gilmore 2005 and references herein). NF-κB activity is repressed by E2 and AEs (Nakshatri et al. 1997, Pratt et al. 2003). Members of the NF-κB/Rel family form dimers that regulate the transcription of genes encoding regulators of proliferation (c-myc and cyclin D1) and inhibitors of apoptosis (Chen & Greene 2004). According to several observations, NF-κB activity is important for mammary carcinogenesis. Several reports have indicated that SERMs (like Tam and raloxifen) as well as SERDs (like ICI) inhibit the NF-κB activity in various cell types (see Biswas et al. 2005 for a review). Thus, most results suggest that inhibiting the NF-κB pathway in BC could have therapeutic effects principally in Tam-resistant tumours treated with E2 (Jordan 2004) or ICI (Riggins et al. 2005a,b).

Effects of oestrogens and AEs in MM

Expression of oestrogen receptors

Oestrogens influence the differentiation, proliferation and survival of haematopoietic cells of the B lineage (Smithson et al. 1998, Medina et al. 2000, Grimaldi et al. 2002) and increase the number of plasma cells and the capacity of these cells to synthesise immunoglobulins (Molina et al. 1999). It is therefore not surprising that normal plasma cells and plasma cells from tumours both produce oestrogen receptor mRNA and protein. Transcripts for both ER subtypes are present in MM cell lines (Fig. 3; Otsuki et al. 2000), together with protein isoforms (Treon et al. 1998, Gauduchon et al. 2005, Maillard et al. 2006, Olivier et al. 2006). However, these proteins are expressed in small amounts and are difficult to detect by immunoblotting. This is particularly true for ERβ, for which the quality of commercially available antibodies is low. In contrast to previous reports (Olivier et al. 2006), we found that the levels of ERα and β in MM cells never reached those in MCF-7 cells (Gauduchon et al. 2003, 2005). As a result, hormone-binding detection assays based on the use of tritiated high-affinity oestrogens have always been unsuccessful in our hands (unpublished data).

Figure 3
Figure 3

Oestradiol receptors in breast cancer and multiple myeloma cells. BC (MCF-7ras, T47D, MDA-MB231, MCF-7) and MM (LP-1, Karpas 620, RPMI 8226, U266, NCl-H929, OPM-2) cells were switched to phenol red-free media containing 10% charcoal-dextran stripped fetal calf serum 3 days before total RNA isolation with Trizol reagent (Invitrogen). Purified RNA was reverse transcribed with M-MuLV reverse transcriptase (Invitrogen), according to the manufacturer's instructions. PCR was carried out with Platinum Taq polymerase (Invitrogen). The primer sequences were as follows: β-actin (forward: 5′-tgacggggtcacccacactgtgcccatcta-3′, reverse: 5′-ctagaagcatttgcggtggacgatggaggg-3′), ERα (forward: 5′-gtggcctcgtttttagtc-3′, reverse: 5′-tcacctgtgagagaacag-3′), ERβ (forward: 5′-tcacatctgtatgcggaacc-3′, reverse: 5′-cgtaacacttccgaagtcgg-3′).

Citation: Journal of Molecular Endocrinology 40, 3; 10.1677/JME-07-0143

Effects of oestrogens and AEs on MM cell proliferation

E2 and AEs are anti-proliferative in MM cells (Treon et al. 1998, Otsuki et al. 2000, Gauduchon et al. 2005, Olivier et al. 2006). At high concentrations (0.5 to 50 μM), AEs arrest the cell cycle in MM cells at the G1 (Gauduchon et al. 2005, Table 2) or the G2 phase (Olivier et al. 2006) depending on the type of AE used. However, in all cases, cell cycle arrest is mediated by the down-regulation of c-myc followed by the up-regulation and redistribution of p21Cip1 and p27Kip1 within the cyclin D/E/Cdk complexes, leading to the hypophosphorylation of pRb (Gauduchon et al. 2005, Olivier et al. 2006, Table 2). A similar situation is observed in BC cells, except that the mediators of AE-mediated cell cycle arrest appear to be cell specific (Sola & Renoir 2007; Fig. 4).

Figure 4
Figure 4

Mechanism of cell cycle arrest in multiple myeloma cells. Cultured LP-1 MM cells were treated with 10 μM RU (+) for 24 h or left untreated (−) and harvested. Total proteins were extracted, separated by SDS-PAGE, transferred onto membranes then incubated with various antibodies (anti-c-Myc, anti-p27Kip1, anti-cyclin D3, anti-phospho-pRb antibodies). In MM cells, RU down-regulates c-Myc, its primary target, and consequently cyclin D3. In the mean time, there is an up-regulation of the cki p27Kip1 that binds the cyclin D3/CDK6 complexes. Finally, the inhibition of cdk activity leads to the hypophosphorylation of pRb and the cell cycle arrest at the G1 phase.

Citation: Journal of Molecular Endocrinology 40, 3; 10.1677/JME-07-0143

Table 2

Antioestrogen-mediated cell cycle arrests and induction of apoptosis in multiple myeloma cells

4-HTRUICI
U266G1 arrest+apoptosisNo responsend
RPMI 8226G1 arrest+apoptosisApoptosisApoptosis
NCI-H929G1 arrest+apoptosisApoptosisApoptosis
OPM-2No responseG1 arrestG1 arrest
Karpas 620No responseNo responsend
LP-1G1 arrest+apoptosisG1 arrestG1 arrest

nd, not determined.

Effects of AEs on the apoptosis of MM cells

In addition to their anti-proliferative activity, AEs also trigger MM cell apoptosis at micromolar concentrations (Table 2; Treon et al. 1998, Otsuki et al. 2000, Gauduchon et al. 2005, Olivier et al. 2006). The fact that U266 and Karpas 620 cell lines are listed as not responsive to RU in the face of being ER positive (Fig. 3) may be due to an insufficient (or no) ER protein expression despite the presence of the mRNAs. In agreement with that, using western blot analysis, we did not see the ER protein in Karpas 620 cells (Gauduchon et al. 2005). The lack of AE response could be also due to the absence of co-activators or overexpression of co-repressors as suggested previously (Shim et al. 2003, Shim et al. 2006, Sola & Renoir 2006). Moreover, the response to 4-HT may be attributable to the production of ROS at micromolar 4-HT concentration.

Cell cycle arrest and apoptosis induction are independent phenomena occurring simultaneously following the treatment with 4-HT and RU or ICI (Gauduchon et al. 2005). AEs activate the mitochondrial intrinsic death pathway (Treon et al. 1998, Otsuki et al. 2000, Gauduchon et al. 2005, Olivier et al. 2006) and may also activate the endoplasmic reticulum death pathway, according to plasma cell physiology. Following the AE-induced apoptotic signal, cytochrome c is released from the mitochondria and activates caspase-9 or caspase-4 and then caspase-3 (Fig. 5). Apoptosis signalling is amplified by the recruitment of caspase-8 and the cleavage of Bid (Maillard et al. 2006), but does not require the extrinsic death receptor pathways mediated by Fas/FasL and DR4/5/TRAIL (our unpublished data).

Figure 5
Figure 5

Schematic illustration of the apoptotic pathways activated by antioestrogens in breast cancer and multiple myeloma cells. At micromolar concentrations, AEs activate the intrinsic mitochondrial pathway by inducing the release of cytochrome c and the successive activation of caspase-9 and caspase-3 in MM cells (replaced by caspase-6/7 in MCF-7 cells), leading to the cleavage of PARP. In MM cells, RU and ICI also induce apoptosis by activating caspase-4, which, in turn activates caspase-3. Finally, the activation of caspase-8 leads to the cleavage of Bid, resulting in the amplification of caspase-9 activation, further increasing the level of apoptosis. ER, endoplasmic reticulum.

Citation: Journal of Molecular Endocrinology 40, 3; 10.1677/JME-07-0143

Effects of AEs on MM survival signalling

MM cells display constitutive activation of survival signalling pathways, including the Ras/mitogen-activated protein kinase (MAPK), Janus kinase (Jak)/signal transducer and activator of transcription (STAT), NF-κB, phosphoinositol-3-kinase (PI3K)/Akt pathways (Bommert et al. 2006). To be effective, anti-myeloma agents must therefore target one or several of these pathways. Moreover, the ability to inhibit survival pathways seems to be essential for the treatment of MM resistant to conventional drugs (Hideshima et al. 2007). As in some BC cells, it has been shown that the NF-κB p65 subunit is associated with ERα in the nucleus of MM cell lines although weakly. Upon raloxifen treatment, there is a transient increase in the p65/NF-κB interaction and simultaneously a loss of p65 binding on specific gene promoters such as mip-1α (Olivier et al. 2006). We do not have evidence of any interaction between ERα and NF-κB subunits in MM cells after RU treatment. Nevertheless, RU induces an inhibition of IκB kinase activity in RPMI 8226 cells that undergo apoptosis (Fig. 6) and inhibits p65 binding on its DNA target (data not shown). RU also interferes with the STAT3 and Akt pathways by modulating the phosphorylation of signal transducers (Fig. 6). However, the demonstration that the inhibition of these survival pathways is necessary for apoptosis triggering needs some additional work.

Figure 6
Figure 6

Effects of RU on survival pathways activated in MM cells. MM cells are characterised by the constitutive activation of pathways involved in survival signalling: PI3K/Akt, Jak/Stat3, Ras/MAPK or NF-κB. This is illustrated by the constitutive phosphorylation of proteins involved in the signalisation cascade. Using phospho-specific antibodies, we analysed the effects of RU on two MM cell lines: LP-1 and RPMI 8226. RU treatment of LP-1 cells blocks cell cycle but has no effects on cell death; by contrast, RU induces RPMI 8226 cell apoptosis but had no effects on cell cycle. The Akt pathway is activated in both cell lines. In LP-1 cells, RU has no effects on pAkt (Ser473 and Thr 308) or the phosphatase PTEN. In RPMI 8226 cells, RU treatment leads to a decrease of Akt and in turn in its phosphorylated form. RPMI 8226 and LP-1 cells display a constitutive activity of p65 NF-κB subunit binding on DNA (not shown). RU treatment has no effects on pIκB, the inhibitor of NF-κB, but up-regulates this form in RPMI 8226. RU has no effects on the MAPK, ERK1/2 and JNK pathways. On the Jak/Stat3 pathway, preliminary results indicate that in RPMI 8226 cells, RU down-regulates pTyr705-Stat3. Experiments are ongoing to determine whether the inhibition of the Jak/Stat3 is necessary for apoptosis to occur.

Citation: Journal of Molecular Endocrinology 40, 3; 10.1677/JME-07-0143

Effects of AEs in MM xenografts

Although not reproducing the exact human pathology, a commonly used model using s.c. injection of RPMI 8226 cells in nude mice was developed (Chauhan et al. 2002, Cuendet et al. 2004). This type of tumour preserves neo-angiogenic characteristics necessary for the development of the disease. Using a stealth liposomal delivery system, we have demonstrated that both RU (Maillard et al. 2005, 2006) and 4-HT (manuscript in preparation) induced a decrease of RPMI 8226 tumour growth. In addition, AE-targeted to solid tumours by delivery systems such as those generated for RPMI 8226 (Maillard et al. 2006) and MCF-7 xenografts induce strong anti-angiogenesis, potentiating the anti-proliferative and apoptotic activities of AEs (Renoir et al. 2006).

Conclusions

These data demonstrate that, in ER-positive BC and MM cell lines, both types of AE arrest the cell cycle and/or induce apoptosis via two independent and separate but similar pathways. Indeed, AEs initially target c-myc and the cell cycle machinery, but cyclin D3 and p27Kip1 in MM cells replacing the cyclin D1 and p21Cip1 targeted in BC cells. AEs trigger the mitochondrial intrinsic death pathway in BC cells and both the mitochondrial and endoplasmic reticulum death pathways in MM cells. ER ligands act in synergy with conventional molecules used in the treatment of cancer, such as dexamethasone, and bortezomib (Jordan 2007, Jordan & Brodie 2007), and encouraging preliminary results for MM xenografts (Maillard et al. 2006) and MM patients (Fassas et al. 2001) provide a rationale for the use of AEs in the clinical treatment of MM. AE compounds may be of greater value for the treatment than the original restriction of their use to E2-dependent BCs might suggest. The chief unresolved question concerns the involvement of ER in mediating the anti-proliferative effects of AEs. Our working hypothesis is that in both BC and MM cells, AE-mediated cell cycle arrest is ER dependent, whereas apoptosis is ER independent. ERs require various co-regulatory proteins for their function (Hall & McDonnell 2005), and the cell-specific expression of these molecules may account for differences in the actions of different ER antagonists. In addition, the discovery of membrane ER-triggered effects and crosstalk with growth factors, NF-κB and kinase cascade signalling (Gee et al. 2003, Kalaitzidis & Gilmore 2005, Martin et al. 2005, Nicholson et al. 2005) has greatly complicated our view of the mechanism of action of ER ligands. However, due to the large tissue distribution of ERs (and mainly ERβ), it is likely that AEs could have some positive or negative effects on various other cancers such as uterine, ovary, lung and colon cancers due to crosstalk with the above-mentioned pathways (AP1, SP1, EGFR, NF-κB, Akt/PKB). More work is clearly required to improve our understanding of the activities of ER ligands regulation of the balance existing between ERα and ERβ.

Acknowledgements

Supported by the Ligue Nationale contre le Cancer - Comités du Cher de l'Indre et des Hauts de Seine (to J-M R), Comités de la Manche et du Calvados (to B S), the Association pour la Recherche sur le Cancer (fellowship to C B and A S). The authors declare no conflict of interest that would prejudice impartiality of the research.

References

  • AltucciLAddeoRCicatielloSDauvoisSParkerMGTrussMBeatoMSicaFBrescianiFWeiszA199617β-Estradiol induces cyclin D1 gene transcription, p36D1-p34cdk4 complex activation and p105Rb phosphorylation during mitogenic stimulation of G(1)-arrested human breast cancer cells. Oncogene1223152324.

    • Search Google Scholar
    • Export Citation
  • AmellerTMarsaudVLegrandPGrefRRenoirJM2003In vitro and in vivo biologic evaluation of long-circulating biodegradable drug carriers loaded with the pure antiestrogen RU 58668. International Journal of Cancer106446454.

    • Search Google Scholar
    • Export Citation
  • BiswasDKSinghSShiQPardeeABIglehartJD2005Crossroads of estrogen receptor and NF-κB signaling. Science's STKE2005pe27

  • BommertKBargouRCStuhmerT2006Signalling and survival pathways in multiple myeloma. European Journal of Cancer4215741580.

  • BurowMEWeldonCBTangYMcLachlanJABeckmanBS2001Oestrogen-mediated suppression of tumour necrosis factor alpha-induced apoptosis in MCF-7 cells: subversion of Bcl-2 by anti-oestrogens. Journal of Steroid Biochemistry and Molecular Biology78409418.

    • Search Google Scholar
    • Export Citation
  • CaldonCEDalyRJSutherlandRLMusgroveEA2006Cell cycle control in breast cancer cells. Journal of Cellular Biochemistry97261274.

  • CampbellRABhat-NakshatriPPatelNMConstantinidouDAliSNakshatriH2001Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. Journal of Biological Chemistry27698179824.

    • Search Google Scholar
    • Export Citation
  • CariouSDonovanJCFlanaganWMMilicABhattacharyaNSlingerlandJM2000Down-regulation of p21WAF1/CIP1 or p27Kip1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells. PNAS9790429046.

    • Search Google Scholar
    • Export Citation
  • CarrollJSPrallOWMusgroveEASutherlandRL2000A pure estrogen antagonist inhibits cyclin E-Cdk2 activity in MCF-7 breast cancer cells and induces accumulation of p130-E2F4 complexes characteristic of quiescence. Journal of Biological Chemistry2753822138229.

    • Search Google Scholar
    • Export Citation
  • CarrollJSLynchDKSwarbrickARenoirJMSarcevicBDalyRJMusgroveEASutherlandRL2003p27(Kip1) induces quiescence and growth factor insensitivity in tamoxifen-treated breast cancer cells. Cancer Research6343224326.

    • Search Google Scholar
    • Export Citation
  • Castro-RiveraESamudioISafeS2001Estrogen regulation of cyclin D1 gene expression in ZR-75 breast cancer cells involves multiple enhancer elements. Journal of Biological Chemistry2763085330861.

    • Search Google Scholar
    • Export Citation
  • ChauhanDCatleyLHideshimaTLiGLeblancRGuptaTSlatterMRichardsonPSchlossmanRPodarK20022-Methoxyestradiol overcomes drug resistance in multiple myeloma cells. Blood10021872194.

    • Search Google Scholar
    • Export Citation
  • ChenLFGreeneWC2004Shaping the nuclear action of NF-κB. Nature Reviews. Molecular Cell Biology5392401.

  • CuendetMChristovKLantvitDDDengYHedayatSHelsonLMcChesneyJDPezzutoJM2004Multiple myeloma regression mediated by bruceantin. Clinical Cancer Research1011701179.

    • Search Google Scholar
    • Export Citation
  • Dahlman-WrightKCavaillesVFuquaSAJordanVCKatzenellenbogenJAKorachKSMaggiAMuramatsuMParkerMGGustafssonJA2006International Union of Pharmacology. LXIV. Estrogen receptors. Pharmacological Reviews58773781.

    • Search Google Scholar
    • Export Citation
  • DindaSSanchezAMoudgilV2002Estrogen-like effects of thyroid hormone on the regulation of tumor suppressor proteins, p53 and retinoblastoma, in breast cancer cells. Oncogene21761768.

    • Search Google Scholar
    • Export Citation
  • Doisneau-SixouSFSergioCMCarrollJSHuiRMusgroveEASutherlandRL2003Estrogen and antiestrogen regulation of cell cycle progression in breast cancer cells. Endocrine Related Cancer10179186.

    • Search Google Scholar
    • Export Citation
  • DuongVBoulleNDaujatSChauvetJBonnetSNeelHCavaillesV2007Differential regulation of estrogen receptor alpha turnover and transactivation by Mdm2 and stress-inducing agents. Cancer Research6755135521.

    • Search Google Scholar
    • Export Citation
  • EllisCAVosMDWicklineMRileyCVallecorsaTTelfordWGZujewskilJClarkGJ2003Tamoxifen and the farnesyl transferase inhibitor FTI-277 synergize to inhibit growth in estrogen receptor-positive breast tumor cell lines. Breast Cancer Research and Treatment785967.

    • Search Google Scholar
    • Export Citation
  • EnmarkEGustafssonJA1999Oestrogen receptors – an overview. Journal of Internal Medicine246133138.

  • FalkensteinETillmannHCChristMFeuringMWehlingM2000Multiple actions of steroid hormones–a focus on rapid, nongenomic effects. Pharmacological Reviews52513556.

    • Search Google Scholar
    • Export Citation
  • FassasABRapoportAPBolanos-MeadeJShanholtzCCottler-FoxMTricotG2001Tamoxifen-based treatment induces clinically meaningful responses in multiple myeloma patients with relapsing disease after autotransplantation. Leukemia and Lymphoma4213231328.

    • Search Google Scholar
    • Export Citation
  • FattmanCLAnBSussmanLDouQP1998p53-independent dephosphorylation and cleavage of retinoblastoma protein during tamoxifen-induced apoptosis in human breast carcinoma cells. Cancer Letters130103113.

    • Search Google Scholar
    • Export Citation
  • FauldsMHOlsenHHelgueroLAGustafssonJAHaldosenLA2004Estrogen receptor functional activity changes during differentiation of mammary epithelial cells. Molecular Endocrinology18412421.

    • Search Google Scholar
    • Export Citation
  • FosterJSWimalasenaJ1996Estrogen regulates activity of cyclin-dependent kinases and retinoblastoma protein phosphorylation in breast cancer cells. Molecular Endocrinology10488498.

    • Search Google Scholar
    • Export Citation
  • FosterJSHenleyDCBukovskyASethPWimalasenaJ2001Multifaceted regulation of cell cycle progression by estrogen: regulation of Cdk inhibitors and Cdc25A independent of cyclin D1-Cdk4 function. Molecular and Cellular Biology21794810.

    • Search Google Scholar
    • Export Citation
  • FosterJSFernandoRIIshidaNNakayamaKIWimalasenaJ2003Estrogens down-regulate p27Kip1 in breast cancer cells through Skp2 and through nuclear export mediated by the ERK pathway. Journal of Biological Chemistry2784135541366.

    • Search Google Scholar
    • Export Citation
  • FrasorJDanesJMKommBChangKCLyttleCRKatzenellenbogenBS2003Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinology14445624574.

    • Search Google Scholar
    • Export Citation
  • FrasorJChangECKommBLinCYVegaVBLiuETMillerLDSmedsJBerghJKatzenellenbogenBS2006Gene expression preferentially regulated by tamoxifen in breast cancer cells and correlations with clinical outcome. Cancer Research6673347340.

    • Search Google Scholar
    • Export Citation
  • GauduchonJGouilleuxFMaillardSMarsaudVRenoirJMSolaB2003The selective estrogen receptor modulator 4-hydroxy tamoxifen induces G1 arrest and apoptosis of multiple myeloma cell lines. Annals of the New York Academy of Sciences1010321325.

    • Search Google Scholar
    • Export Citation
  • GauduchonJGouilleuxFMaillardSMarsaudVRenoirJMSolaB2005The 4-hydroxytamoxifen inhibits proliferation of multiple myeloma cells in vitro and in vivo through down-regulation of c-Myc, up-regulation of p27Kip1 and modulation of Bcl-2 family members. Clinical Cancer Research1123452354.

    • Search Google Scholar
    • Export Citation
  • GeeJMHarperMEHutchesonIRMaddenTABarrowDKnowldenJMMcClellandRAJordanNWakelingAENicholsonRI2003The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitro. Endocrinology14451055117.

    • Search Google Scholar
    • Export Citation
  • GlarosSAtanaskovaNZhaoCSkafarDFReddyKB2006Activation function-1 domain of estrogen receptor regulates the agonistic and antagonistic actions of tamoxifen. Molecular Endocrinology209961008.

    • Search Google Scholar
    • Export Citation
  • GompelASomaiSChaouatMKazenAKloosterboerHJBeusmanIForgezPMimounMRosteneW2000Hormonal regulation of apoptosis in breast cells and tissues. Steroids65593598.

    • Search Google Scholar
    • Export Citation
  • GottardisMMRobinsonSPSatyaswaroopPGJordanVC1988Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. Cancer Research48812815.

    • Search Google Scholar
    • Export Citation
  • GreenSKumarVTheulazIWahliWChambonP1988The N-terminal DNA-binding ‘zinc finger’ of the oestrogen and glucocorticoid receptors determines target gene specificity. EMBO Journal730373044.

    • Search Google Scholar
    • Export Citation
  • GrimaldiCMClearyJDagtasASMoussaiDDiamondB2002Estrogen alters thresholds for B cell apoptosis and activation. Journal of Clinical Investigation10916251633.

    • Search Google Scholar
    • Export Citation
  • HallJMMcDonnellDP1999The estrogen receptor beta-isoform (ERβ) of the human estrogen receptor modulates ERα transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. Endocrinology14055665578.

    • Search Google Scholar
    • Export Citation
  • HallJMMcDonnellDP2005Coregulators in nuclear estrogen receptor action: from concept to therapeutic targeting. Molecular Interventions5343357.

    • Search Google Scholar
    • Export Citation
  • HansteinBDjahansouziSDallPBeckmanMWBenderHG2004Insights into the molecular biology of the estrogen receptor define novel therapeutic targets for breast cancer. European Journal of Endocrinology150243255.

    • Search Google Scholar
    • Export Citation
  • HaydenMSGhoshS2004Signaling to NF-κB. Genes and Development1821952224.

  • HeldringNPikeAAnderssonSMatthewsJChengGHartmanJTujagueMStromATreuterEWarnerM2007Estrogen receptors: how do they signal and what are their targets. Physiological Reviews87905931.

    • Search Google Scholar
    • Export Citation
  • HideshimaTMitsiadesCTononGRichardsonPGAndersonKC2007Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nature Reviews. Cancer7585598.

    • Search Google Scholar
    • Export Citation
  • HolstFStahlPRRuizCHellwinkelOJehanZWendlandMLebeauATerraccianoLAl-KurayaKJanickeF2007Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer. Nature Genetics39655660.

    • Search Google Scholar
    • Export Citation
  • HurJChesnesJCoserKRLeeRSGeckPIsselbacherKJShiodaT2004The Bik BH3-only protein is induced in estrogen-starved and antiestrogen-exposed breast cancer cells and provokes apoptosis. PNAS10123512356.

    • Search Google Scholar
    • Export Citation
  • HurdCKhattreeNDindaSAlbanPMoudgilVK1997Regulation of tumor suppressor proteins, p53 and retinoblastoma, by estrogen and antiestrogens in breast cancer cells. Oncogene15991995.

    • Search Google Scholar
    • Export Citation
  • JamersonMHJohnsonMDDicksonRB2004Of mice and Myc: c-Myc and mammary tumorigenesis. Journal of Mammary Gland Biology and Neoplasia92737.

    • Search Google Scholar
    • Export Citation
  • JanickeRUSprengartMLWatiMRPorterAG1998Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. Journal of Biological Chemistry27393579360.

    • Search Google Scholar
    • Export Citation
  • JordanVC2004Selective estrogen receptor modulation: concept and consequences in cancer. Cancer Cell5207213.

  • JordanVC2007SERMs: meeting the promise of multifunctional medicines. Journal of the National Cancer Institute99350356.

  • JordanVCBrodieAM2007Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer. Steroids72725.

    • Search Google Scholar
    • Export Citation
  • JordanVCLewisJSOsipoCChengD2005The apoptotic action of estrogen following exhaustive antihormonal therapy: a new clinical treatment strategy. Breast14624630.

    • Search Google Scholar
    • Export Citation
  • KalaitzidisDGilmoreTD2005Transcription factor cross-talk: the estrogen receptor and NF-κB. Trends in Endocrinology and Metabolism164652.

    • Search Google Scholar
    • Export Citation
  • KallioAZhengADahllundJHeiskanenKMHarkonenP2005Role of mitochondria in tamoxifen-induced rapid death of MCF-7 breast cancer cells. Apoptosis1013951410.

    • Search Google Scholar
    • Export Citation
  • KandouzMLombetAPerrotJYJacobDCarvajalSKazemARosteneWTherwathAGompelA1999Proapoptotic effects of antiestrogens, progestins and androgen in breast cancer cells. Journal of Steroid Biochemistry and Molecular Biology69463471.

    • Search Google Scholar
    • Export Citation
  • KuiperGGEnmarkEPelto-HuikkoMNilssonSGustafssonJA1996Cloning of a novel receptor expressed in rat prostate and ovary. PNAS9359255930.

  • LeungLKDoLWangTT1998Regulation of death promoter Bak expression by cell density and 17 beta-estradiol in MCF-7 cells. Cancer Letters1244752.

    • Search Google Scholar
    • Export Citation
  • LewisJSMeekeKOsipoCRossEAKidawiNLiTBellEChandelNSJordanVC2005Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation. Journal of the National Cancer Institute9717461759.

    • Search Google Scholar
    • Export Citation
  • LillingGNordenbergJRotterVGoldfingerNPellerSSidiY2002Altered subcellular localization of p53 in estrogen-dependent and estrogen-independent breast cancer cells. Cancer Investigation20509517.

    • Search Google Scholar
    • Export Citation
  • LindbergMKMoverareSSkrticSGaoHDahlamn-WrightKGustafssonJAOhlssonC2003Estrogen receptor (ER)-β reduces ERα-regulated gene transcription, supporting a ‘ying yang’ relationship between ERα and ERβ in mice. Molecular Endocrinology17203208.

    • Search Google Scholar
    • Export Citation
  • LiuMMAlbaneseCAndersonCMHiltyKWebbPUhtRMPriceRH JrPestellRGKushnerPJ2002Opposing action of estrogen receptors alpha and beta on cyclin D1 gene expression. Journal of Biological Chemistry2772435324360.

    • Search Google Scholar
    • Export Citation
  • LiuWKonduriSDBansalSNayakBKRajasekaranSAKaruppayilSMRajasekaranAKDasGM2006Estrogen receptor-alpha binds p53 tumor suppressor protein directly and represses its function. Journal of Biological Chemistry28198379840.

    • Search Google Scholar
    • Export Citation
  • LonardDMO'MalleyBW2007Nuclear receptor coregulators: judges, juries, and executioners of cellular regulation. Molecular Cell27691700.

    • Search Google Scholar
    • Export Citation
  • LuoJManningBDCantleyLC2003Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell4257262.

  • MaillardSAmellerTGauduchonJGougeletAGouilleuxFLegrandPMarsaudVFattalESolaBRenoirJM2005Innovative drug delivery nanosystems improve the anti-tumor activity in vitro and in vivo of anti-estrogens in human breast cancer and multiple myeloma. Journal of Steroid Biochemistry and Molecular Biology94111121.

    • Search Google Scholar
    • Export Citation
  • MaillardSGauduchonJMarsaudVGouilleuxFConnaultEOpolonPFattalESolaBRenoirJM2006Improved antitumoral properties of pure antiestrogen RU 58668-loaded liposomes in multiple myeloma. Journal of Steroid Biochemistry and Molecular Biology1006778.

    • Search Google Scholar
    • Export Citation
  • MandlekarSYuRTanTHKongAN2000Activation of caspase-3 and c-Jun NH2-terminal kinase-1 signaling pathways in tamoxifen-induced apoptosis of human breast cancer cells. Cancer Research6059956000.

    • Search Google Scholar
    • Export Citation
  • MartinLAFarmerIJohnstonSRAliSDowsetM2005Elevated ERK1/ERK2/estrogen receptor cross-talk enhances estrogen-mediated signaling during long-term estrogen deprivation. Endocrine-Related Cancer12S75S84.

    • Search Google Scholar
    • Export Citation
  • MatthewsJWihlenBTujagueMWanJSttromAGustafssonJA2006Estrogen receptor (ER) β modulates ERα-mediated transcriptional activation by altering the recruitment of c-Fos and c-Jun to estrogen-responsive promoters. Molecular Endocrinology20534543.

    • Search Google Scholar
    • Export Citation
  • MedinaKLStrasserAKincadePW2000Estrogen influences the differentiation, proliferation, and survival of early B-lineage precursors. Blood9520592067.

    • Search Google Scholar
    • Export Citation
  • MichalidesRGriekspoorABalkenendeAVerwoerdDJanssenLJalinkKFlooreAVeldsAvan't VeerLNeefjesJ2004Tamoxifen resistance by a conformational arrest of the estrogen receptor alpha after PKA activation in breast cancer. Cancer Cell5597605.

    • Search Google Scholar
    • Export Citation
  • MolinaJMassoFPaezAMendezCRodriguezEMandokiJJDiaz de LeonLMontanoLF1999Differential effect of estradiol on antibody secretion of murine hybridomas. Hybridoma18377383.

    • Search Google Scholar
    • Export Citation
  • MolinariAMBontempoPSchiavoneEMTortoraVVerdiccioMANapolitanoMNolaEMontcharmontBMediciNNigroV2000Estradiol induces functional inactivation of p53 by intracellular redistribution. Cancer Research6025942597.

    • Search Google Scholar
    • Export Citation
  • MossRLGuQWongMEstrogen: nontranscriptional signaling pathway(discussion 68–9)Recent Progress in Hormone Research5219973368.

  • MosselmanSPolmanJDijkemaR1996ER β: identification and characterization of a novel human estrogen receptor. FEBS Letters3924953.

  • MuraokaRSLenferinkAESimpsonJBrantleyDMRoebuckLRYakesFMArteagaCL2001Cyclin-dependent kinase inhibitor p27(Kip1) is required for mouse mammary gland morphogenesis and function. Journal of Cell Biology153917932.

    • Search Google Scholar
    • Export Citation
  • MusgroveEAHamiltonJALeeCSSweeneyKJWattsCKSutherlandRL1993Growth factor, steroid, and steroid antagonist regulation of cyclin gene expression associated with changes in T-47D human breast cancer cell cycle progression. Molecular and Cellular Biology1335773587.

    • Search Google Scholar
    • Export Citation
  • NagarkattiNDavisBA2003Tamoxifen induces apoptosis in Fas+ tumor cells by upregulating the expression of Fas ligand. Cancer Chemotherapy and Pharmacology51284290.

    • Search Google Scholar
    • Export Citation
  • NakshatriHBhat-NakshatriPMartinDAGouletRJ JrSledgeGW Jr1997Constitutive activation of NF-κB during progression of breast cancer to hormone-independent growth. Molecular and Cellular Biology1736293639.

    • Search Google Scholar
    • Export Citation
  • NicholsonRIHutchesonIRBrittonDKnowldenJMJonesHEHarperMEHiscoxSEBarrowDGeeJM2005Growth factor signalling networks in breast cancer and resistance to endocrine agents: new therapeutic strategies. Journal of Steroid Biochemistry and Molecular Biology93257262.

    • Search Google Scholar
    • Export Citation
  • ObreroMYuDVShapiroDJ2002Estrogen receptor-dependent and estrogen receptor-independent pathways for tamoxifen and 4-hydroxytamoxifen-induced programmed cell death. Journal of Biological Chemistry2774569545703.

    • Search Google Scholar
    • Export Citation
  • OlivierSClosePCastermansEde LevalLTabruynSChariotAMalaiseMMervilleMPBoursVFranchimontN2006Raloxifene-induced myeloma cell apoptosis: a study of nuclear factor-κB inhibition and gene expression signature. Molecular Pharmacology6916151623.

    • Search Google Scholar
    • Export Citation
  • O'MalleyBW2005A life-long search for the molecular pathways of steroid hormone action. Molecular Endocrinology1914021411.

  • OsborneCKSchiffR2005Estrogen-receptor biology: continuing progress and therapeutic implications. Journal of Clinical Oncology2316161622.

    • Search Google Scholar
    • Export Citation
  • OtsukiTYamadaOKurebayashiJMoriyaTSakaguchiHKunisieHYataKUnoMYawataYUekiA2000Estrogen receptors in human myeloma cells. Cancer Research6014341441.

    • Search Google Scholar
    • Export Citation
  • Planas-SilvaMDWeinbergRA1997Estrogen-dependent cyclin E-cdk2 activation through p21 redistribution. Molecular and Cellular Biology1740594069.

    • Search Google Scholar
    • Export Citation
  • PopovVMWangCShirleyLARosenbergALiSNevalainenMFuMPestellRG2007The functional significance of nuclear receptor acetylation. Steroids72221230.

    • Search Google Scholar
    • Export Citation
  • PrallOWSarcevicBMusgroveEWattsCKSutherlandRL1997Estrogen-induced activation of Cdk4 and Cdk2 during G1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-Cdk2. Journal of Biological Chemistry2721088210894.

    • Search Google Scholar
    • Export Citation
  • PrallOWRoganEMMusgroveEAWattsCKSutherlandRL1998c-Myc or cyclin D1 mimics estrogen effects on cyclin E-Cdk2 activation and cell cycle reentry. Molecular and Cellular Biology1844994508.

    • Search Google Scholar
    • Export Citation
  • PrallOWCarrollJSSutherlandRL2001A low abundance pool of nascent p21WAF1/Cip1 is targeted by estrogen to activate cyclin E*Cdk2. Journal of Biological Chemistry2764543345442.

    • Search Google Scholar
    • Export Citation
  • PrattMABishopTEWhiteDYasvinskiGMenardMNiuNYClarkeR2003Estrogen withdrawal-induced NF-κB activity and bcl-3 expression in breast cancer cells: roles in growth and hormone independence. Molecular and Cellular Biology2368876900.

    • Search Google Scholar
    • Export Citation
  • RayAPrefontaineKERayP1994Down-modulation of interleukin-6 gene expression by 17 beta-estradiol in the absence of high affinity DNA binding by the estrogen receptor. Journal of Biological Chemistry2691294012946.

    • Search Google Scholar
    • Export Citation
  • RenoirJMStellaBAmellerTConnaultEOpolonPMarsaudV2006Improved anti-tumoral capacity of mixed and pure anti-oestrogens in breast cancer cell xenografts after their administration by entrapment in colloidal nanosystems. Journal of Steroid Biochemistry and Molecular Biology102114127.

    • Search Google Scholar
    • Export Citation
  • RigginsRBBoutonAHLiuMCClarkeR2005aAntiestrogens, aromatase inhibitors, and apoptosis in breast cancer. Vitamins and Hormones71201237.

    • Search Google Scholar
    • Export Citation
  • RigginsRBZwartANehraRClarkeR2005bThe nuclear factor kappa B inhibitor parthenolide restores ICI 182,780 (Faslodex; fulvestrant)-induced apoptosis in antiestrogen-resistant breast cancer cells. Molecular Cancer Therapeutics43341.

    • Search Google Scholar
    • Export Citation
  • SabbahMCourilleauDMesterJRedeuilhG1999Estrogen induction of the cyclin D1 promoter: involvement of a cAMP response-like element. PNAS961121711222.

    • Search Google Scholar
    • Export Citation
  • SayeedAKonduriSDLiuWBansalSLiFDasGM2007Estrogen receptor alpha inhibits p53-mediated transcriptional repression: implications for the regulation of apoptosis. Cancer Research6777467755.

    • Search Google Scholar
    • Export Citation
  • SherrCJRobertsJM1999CDK inhibitors: positive and negative regulators of G1-phase progression. Genes and Development1315011512.

  • ShimGJWangLAnderssonSNagyNKisLLZhangQMakelaSWarnerMGustafssonJA2003Disruption of the estrogen receptor beta gene in mice causes myeloproliferative disease resembling chronic myeloid leukemia with lymphoid blast crisis. PNAS10066946699.

    • Search Google Scholar
    • Export Citation
  • ShimGJGhermanDKimHJOmotoYIwaseHBoutonDKisLLAnderssonCTWarnerMGustafssonJA2006Differential expression of oestrogen receptors in human secondary lymphoid tissues. Journal of Pathology208408414.

    • Search Google Scholar
    • Export Citation
  • SlingerlandJPaganoM2000Regulation of the cdk inhibitor p27 and its deregulation in cancer. Journal of Cellular Physiology1831017.

  • SmithsonGCouseJFLubahnDBKorachKSKincadePW1998The role of estrogen receptors and androgen receptors in sex steroid regulation of B lymphopoiesis. Journal of Immunology1612734.

    • Search Google Scholar
    • Export Citation
  • SmolnikarKLoffekSSchulzTMichnaHDielP2000Treatment with the pure antiestrogen faslodex (ICI 182780) induces tumor necrosis factor receptor 1 (TNFR1) expression in MCF-7 breast cancer cells. Breast Cancer Research and Treatment63249259.

    • Search Google Scholar
    • Export Citation
  • SolaBRenoirJM2006Antiestrogenic therapies in solid cancers and multiple myeloma. Current Molecular Medicine6359368.

  • SolaBRenoirJM2007Estrogenic or antiestrogenic therapies for multiple myeloma?Molecular Cancer659

  • SomaiSChaouatMJacobDPerrotJYRosteneWForgezPGompelA2003Antiestrogens are pro-apoptotic in normal human breast epithelial cells. International Journal of Cancer105607612.

    • Search Google Scholar
    • Export Citation
  • SongRXSantenRJ2003Apoptotic action of estrogen. Apoptosis85560.

  • SongRXFanPYueWChenYSantanRJRole of receptor complexes in the extranuclear actions of estrogen receptor alpha in breast cancerEndocrine-Related Cancer13Suppl 12006S3S13.

    • Search Google Scholar
    • Export Citation
  • StrasserAO'ConnorLDixitVM2000Apoptosis signaling. Annual Review of Biochemistry69217245.

  • StromAHartmanJFosterJSKietzSWimalasenaJGustafssonJA2004Estrogen receptor beta inhibits 17β-estradiol-stimulated proliferation of the breast cancer cell line T47D. PNAS10115661571.

    • Search Google Scholar
    • Export Citation
  • SunMPacigaJEFeldmanRIYuanZCoppolaDLuYYShelleySANicosiaSVChengJQ2001Phosphatidylinositol-3-OH Kinase (PI3K)/AKT2, activated in breast cancer, regulates and is induced by estrogen receptor alpha (ERα) via interaction between ERα and PI3K. Cancer Research6159855991.

    • Search Google Scholar
    • Export Citation
  • ThiantanawatALongBJBrodieAM2003Signaling pathways of apoptosis activated by aromatase inhibitors and antiestrogens. Cancer Research6380378050.

    • Search Google Scholar
    • Export Citation
  • TreonSPTeohGUrashimaMOgataAChauhanDWebbIJAndersonKC1998Anti-estrogens induce apoptosis of multiple myeloma cells. Blood9217491757.

  • TsaiEMWangSCLeeJNHungMC2001Akt activation by estrogen in estrogen receptor-negative breast cancer cells. Cancer Research6183908392.

  • WatsonPHPonRTShiuRP1991Inhibition of c-myc expression by phosphorothioate antisense oligonucleotide identifies a critical role for c-myc in the growth of human breast cancer. Cancer Research5139964000.

    • Search Google Scholar
    • Export Citation
  • WattsCKBradyASarcevicBDeFazioAMusgroveEASutherlandRL1995Antiestrogen inhibition of cell cycle progression in breast cancer cells in associated with inhibition of cyclin-dependent kinase activity and decreased retinoblastoma protein phosphorylation. Molecular Endocrinology918041813.

    • Search Google Scholar
    • Export Citation
  • ZhangGJKimijimaIOndaMKannoMSatoHWatanabeTTsuchiyaAAbeRTakenoshitaS1999Tamoxifen-induced apoptosis in breast cancer cells relates to down-regulation of bcl-2, but not bax and bcl-X(L), without alteration of p53 protein levels. Clinical Cancer Research529712977.

    • Search Google Scholar
    • Export Citation
  • ZhengAKallioAHarkonenP2007Tamoxifen-induced rapid death of MCF-7 breast cancer cells is mediated via extracellularly signal-regulated kinase signaling and can be abrogated by estrogen. Endocrinology14827642777.

    • Search Google Scholar
    • Export Citation

If the inline PDF is not rendering correctly, you can download the PDF file here.

 

      Society for Endocrinology

Sept 2018 onwards Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 960 91 4
PDF Downloads 160 67 5
  • View in gallery

    Chemical structures of antioestrogens. 4-hydroxy-tamoxifen (4-HT), the active metabolite of tamoxifen and raloxifen belong to the selective oestrogen receptor modulator (SERMs) family. The members of this family act either as E2-agonists or -antagonists depending on ER subtype and cell context. ICI 182 780 and RU58668 are selective oestrogen receptor down-regulators (SERDs), acting as pure antioestrogens.

  • View in gallery

    Schematic illustration of the activities of oestradiol and antioestrogens in MCF-7 cells. Following E2 treatment, a rapid transcription-mediated increase in c-myc expression occurs, facilitating cyclin E–Cdk2 activation and entry into S phase. Concomitantly, E2 down-regulates p21Cip1 and p27Kip1 and increases cyclin D1 levels. The formation of complexes containing Cdk4 and sequestrating Ckis is enhanced. Ckis levels are down-regulated upon c-myc expression. All these events initiate the phosphorylation of pRb. Cyclin D1 in bold typeface: increase in cyclin D1 levels with activated cyclin–Cdk complexes; *increase in Cdk activity. In grey boxes, low levels of Cki. In black, E2-mediated effects. In red, AE-mediated inhibition leading to cell cycle arrest in G0/G1. Refer to text for details and references.

  • View in gallery

    Oestradiol receptors in breast cancer and multiple myeloma cells. BC (MCF-7ras, T47D, MDA-MB231, MCF-7) and MM (LP-1, Karpas 620, RPMI 8226, U266, NCl-H929, OPM-2) cells were switched to phenol red-free media containing 10% charcoal-dextran stripped fetal calf serum 3 days before total RNA isolation with Trizol reagent (Invitrogen). Purified RNA was reverse transcribed with M-MuLV reverse transcriptase (Invitrogen), according to the manufacturer's instructions. PCR was carried out with Platinum Taq polymerase (Invitrogen). The primer sequences were as follows: β-actin (forward: 5′-tgacggggtcacccacactgtgcccatcta-3′, reverse: 5′-ctagaagcatttgcggtggacgatggaggg-3′), ERα (forward: 5′-gtggcctcgtttttagtc-3′, reverse: 5′-tcacctgtgagagaacag-3′), ERβ (forward: 5′-tcacatctgtatgcggaacc-3′, reverse: 5′-cgtaacacttccgaagtcgg-3′).

  • View in gallery

    Mechanism of cell cycle arrest in multiple myeloma cells. Cultured LP-1 MM cells were treated with 10 μM RU (+) for 24 h or left untreated (−) and harvested. Total proteins were extracted, separated by SDS-PAGE, transferred onto membranes then incubated with various antibodies (anti-c-Myc, anti-p27Kip1, anti-cyclin D3, anti-phospho-pRb antibodies). In MM cells, RU down-regulates c-Myc, its primary target, and consequently cyclin D3. In the mean time, there is an up-regulation of the cki p27Kip1 that binds the cyclin D3/CDK6 complexes. Finally, the inhibition of cdk activity leads to the hypophosphorylation of pRb and the cell cycle arrest at the G1 phase.

  • View in gallery

    Schematic illustration of the apoptotic pathways activated by antioestrogens in breast cancer and multiple myeloma cells. At micromolar concentrations, AEs activate the intrinsic mitochondrial pathway by inducing the release of cytochrome c and the successive activation of caspase-9 and caspase-3 in MM cells (replaced by caspase-6/7 in MCF-7 cells), leading to the cleavage of PARP. In MM cells, RU and ICI also induce apoptosis by activating caspase-4, which, in turn activates caspase-3. Finally, the activation of caspase-8 leads to the cleavage of Bid, resulting in the amplification of caspase-9 activation, further increasing the level of apoptosis. ER, endoplasmic reticulum.

  • View in gallery

    Effects of RU on survival pathways activated in MM cells. MM cells are characterised by the constitutive activation of pathways involved in survival signalling: PI3K/Akt, Jak/Stat3, Ras/MAPK or NF-κB. This is illustrated by the constitutive phosphorylation of proteins involved in the signalisation cascade. Using phospho-specific antibodies, we analysed the effects of RU on two MM cell lines: LP-1 and RPMI 8226. RU treatment of LP-1 cells blocks cell cycle but has no effects on cell death; by contrast, RU induces RPMI 8226 cell apoptosis but had no effects on cell cycle. The Akt pathway is activated in both cell lines. In LP-1 cells, RU has no effects on pAkt (Ser473 and Thr 308) or the phosphatase PTEN. In RPMI 8226 cells, RU treatment leads to a decrease of Akt and in turn in its phosphorylated form. RPMI 8226 and LP-1 cells display a constitutive activity of p65 NF-κB subunit binding on DNA (not shown). RU treatment has no effects on pIκB, the inhibitor of NF-κB, but up-regulates this form in RPMI 8226. RU has no effects on the MAPK, ERK1/2 and JNK pathways. On the Jak/Stat3 pathway, preliminary results indicate that in RPMI 8226 cells, RU down-regulates pTyr705-Stat3. Experiments are ongoing to determine whether the inhibition of the Jak/Stat3 is necessary for apoptosis to occur.

  • AltucciLAddeoRCicatielloSDauvoisSParkerMGTrussMBeatoMSicaFBrescianiFWeiszA199617β-Estradiol induces cyclin D1 gene transcription, p36D1-p34cdk4 complex activation and p105Rb phosphorylation during mitogenic stimulation of G(1)-arrested human breast cancer cells. Oncogene1223152324.

    • Search Google Scholar
    • Export Citation
  • AmellerTMarsaudVLegrandPGrefRRenoirJM2003In vitro and in vivo biologic evaluation of long-circulating biodegradable drug carriers loaded with the pure antiestrogen RU 58668. International Journal of Cancer106446454.

    • Search Google Scholar
    • Export Citation
  • BiswasDKSinghSShiQPardeeABIglehartJD2005Crossroads of estrogen receptor and NF-κB signaling. Science's STKE2005pe27

  • BommertKBargouRCStuhmerT2006Signalling and survival pathways in multiple myeloma. European Journal of Cancer4215741580.

  • BurowMEWeldonCBTangYMcLachlanJABeckmanBS2001Oestrogen-mediated suppression of tumour necrosis factor alpha-induced apoptosis in MCF-7 cells: subversion of Bcl-2 by anti-oestrogens. Journal of Steroid Biochemistry and Molecular Biology78409418.

    • Search Google Scholar
    • Export Citation
  • CaldonCEDalyRJSutherlandRLMusgroveEA2006Cell cycle control in breast cancer cells. Journal of Cellular Biochemistry97261274.

  • CampbellRABhat-NakshatriPPatelNMConstantinidouDAliSNakshatriH2001Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. Journal of Biological Chemistry27698179824.

    • Search Google Scholar
    • Export Citation
  • CariouSDonovanJCFlanaganWMMilicABhattacharyaNSlingerlandJM2000Down-regulation of p21WAF1/CIP1 or p27Kip1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells. PNAS9790429046.

    • Search Google Scholar
    • Export Citation
  • CarrollJSPrallOWMusgroveEASutherlandRL2000A pure estrogen antagonist inhibits cyclin E-Cdk2 activity in MCF-7 breast cancer cells and induces accumulation of p130-E2F4 complexes characteristic of quiescence. Journal of Biological Chemistry2753822138229.

    • Search Google Scholar
    • Export Citation
  • CarrollJSLynchDKSwarbrickARenoirJMSarcevicBDalyRJMusgroveEASutherlandRL2003p27(Kip1) induces quiescence and growth factor insensitivity in tamoxifen-treated breast cancer cells. Cancer Research6343224326.

    • Search Google Scholar
    • Export Citation
  • Castro-RiveraESamudioISafeS2001Estrogen regulation of cyclin D1 gene expression in ZR-75 breast cancer cells involves multiple enhancer elements. Journal of Biological Chemistry2763085330861.

    • Search Google Scholar
    • Export Citation
  • ChauhanDCatleyLHideshimaTLiGLeblancRGuptaTSlatterMRichardsonPSchlossmanRPodarK20022-Methoxyestradiol overcomes drug resistance in multiple myeloma cells. Blood10021872194.

    • Search Google Scholar
    • Export Citation
  • ChenLFGreeneWC2004Shaping the nuclear action of NF-κB. Nature Reviews. Molecular Cell Biology5392401.

  • CuendetMChristovKLantvitDDDengYHedayatSHelsonLMcChesneyJDPezzutoJM2004Multiple myeloma regression mediated by bruceantin. Clinical Cancer Research1011701179.

    • Search Google Scholar
    • Export Citation
  • Dahlman-WrightKCavaillesVFuquaSAJordanVCKatzenellenbogenJAKorachKSMaggiAMuramatsuMParkerMGGustafssonJA2006International Union of Pharmacology. LXIV. Estrogen receptors. Pharmacological Reviews58773781.

    • Search Google Scholar
    • Export Citation
  • DindaSSanchezAMoudgilV2002Estrogen-like effects of thyroid hormone on the regulation of tumor suppressor proteins, p53 and retinoblastoma, in breast cancer cells. Oncogene21761768.

    • Search Google Scholar
    • Export Citation
  • Doisneau-SixouSFSergioCMCarrollJSHuiRMusgroveEASutherlandRL2003Estrogen and antiestrogen regulation of cell cycle progression in breast cancer cells. Endocrine Related Cancer10179186.

    • Search Google Scholar
    • Export Citation
  • DuongVBoulleNDaujatSChauvetJBonnetSNeelHCavaillesV2007Differential regulation of estrogen receptor alpha turnover and transactivation by Mdm2 and stress-inducing agents. Cancer Research6755135521.

    • Search Google Scholar
    • Export Citation
  • EllisCAVosMDWicklineMRileyCVallecorsaTTelfordWGZujewskilJClarkGJ2003Tamoxifen and the farnesyl transferase inhibitor FTI-277 synergize to inhibit growth in estrogen receptor-positive breast tumor cell lines. Breast Cancer Research and Treatment785967.

    • Search Google Scholar
    • Export Citation
  • EnmarkEGustafssonJA1999Oestrogen receptors – an overview. Journal of Internal Medicine246133138.

  • FalkensteinETillmannHCChristMFeuringMWehlingM2000Multiple actions of steroid hormones–a focus on rapid, nongenomic effects. Pharmacological Reviews52513556.

    • Search Google Scholar
    • Export Citation
  • FassasABRapoportAPBolanos-MeadeJShanholtzCCottler-FoxMTricotG2001Tamoxifen-based treatment induces clinically meaningful responses in multiple myeloma patients with relapsing disease after autotransplantation. Leukemia and Lymphoma4213231328.

    • Search Google Scholar
    • Export Citation
  • FattmanCLAnBSussmanLDouQP1998p53-independent dephosphorylation and cleavage of retinoblastoma protein during tamoxifen-induced apoptosis in human breast carcinoma cells. Cancer Letters130103113.

    • Search Google Scholar
    • Export Citation
  • FauldsMHOlsenHHelgueroLAGustafssonJAHaldosenLA2004Estrogen receptor functional activity changes during differentiation of mammary epithelial cells. Molecular Endocrinology18412421.

    • Search Google Scholar
    • Export Citation
  • FosterJSWimalasenaJ1996Estrogen regulates activity of cyclin-dependent kinases and retinoblastoma protein phosphorylation in breast cancer cells. Molecular Endocrinology10488498.

    • Search Google Scholar
    • Export Citation
  • FosterJSHenleyDCBukovskyASethPWimalasenaJ2001Multifaceted regulation of cell cycle progression by estrogen: regulation of Cdk inhibitors and Cdc25A independent of cyclin D1-Cdk4 function. Molecular and Cellular Biology21794810.

    • Search Google Scholar
    • Export Citation
  • FosterJSFernandoRIIshidaNNakayamaKIWimalasenaJ2003Estrogens down-regulate p27Kip1 in breast cancer cells through Skp2 and through nuclear export mediated by the ERK pathway. Journal of Biological Chemistry2784135541366.

    • Search Google Scholar
    • Export Citation
  • FrasorJDanesJMKommBChangKCLyttleCRKatzenellenbogenBS2003Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinology14445624574.

    • Search Google Scholar
    • Export Citation
  • FrasorJChangECKommBLinCYVegaVBLiuETMillerLDSmedsJBerghJKatzenellenbogenBS2006Gene expression preferentially regulated by tamoxifen in breast cancer cells and correlations with clinical outcome. Cancer Research6673347340.

    • Search Google Scholar
    • Export Citation
  • GauduchonJGouilleuxFMaillardSMarsaudVRenoirJMSolaB2003The selective estrogen receptor modulator 4-hydroxy tamoxifen induces G1 arrest and apoptosis of multiple myeloma cell lines. Annals of the New York Academy of Sciences1010321325.

    • Search Google Scholar
    • Export Citation
  • GauduchonJGouilleuxFMaillardSMarsaudVRenoirJMSolaB2005The 4-hydroxytamoxifen inhibits proliferation of multiple myeloma cells in vitro and in vivo through down-regulation of c-Myc, up-regulation of p27Kip1 and modulation of Bcl-2 family members. Clinical Cancer Research1123452354.

    • Search Google Scholar
    • Export Citation
  • GeeJMHarperMEHutchesonIRMaddenTABarrowDKnowldenJMMcClellandRAJordanNWakelingAENicholsonRI2003The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitro. Endocrinology14451055117.

    • Search Google Scholar
    • Export Citation
  • GlarosSAtanaskovaNZhaoCSkafarDFReddyKB2006Activation function-1 domain of estrogen receptor regulates the agonistic and antagonistic actions of tamoxifen. Molecular Endocrinology209961008.

    • Search Google Scholar
    • Export Citation
  • GompelASomaiSChaouatMKazenAKloosterboerHJBeusmanIForgezPMimounMRosteneW2000Hormonal regulation of apoptosis in breast cells and tissues. Steroids65593598.

    • Search Google Scholar
    • Export Citation
  • GottardisMMRobinsonSPSatyaswaroopPGJordanVC1988Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. Cancer Research48812815.

    • Search Google Scholar
    • Export Citation
  • GreenSKumarVTheulazIWahliWChambonP1988The N-terminal DNA-binding ‘zinc finger’ of the oestrogen and glucocorticoid receptors determines target gene specificity. EMBO Journal730373044.

    • Search Google Scholar
    • Export Citation
  • GrimaldiCMClearyJDagtasASMoussaiDDiamondB2002Estrogen alters thresholds for B cell apoptosis and activation. Journal of Clinical Investigation10916251633.

    • Search Google Scholar
    • Export Citation
  • HallJMMcDonnellDP1999The estrogen receptor beta-isoform (ERβ) of the human estrogen receptor modulates ERα transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. Endocrinology14055665578.

    • Search Google Scholar
    • Export Citation
  • HallJMMcDonnellDP2005Coregulators in nuclear estrogen receptor action: from concept to therapeutic targeting. Molecular Interventions5343357.

    • Search Google Scholar
    • Export Citation
  • HansteinBDjahansouziSDallPBeckmanMWBenderHG2004Insights into the molecular biology of the estrogen receptor define novel therapeutic targets for breast cancer. European Journal of Endocrinology150243255.

    • Search Google Scholar
    • Export Citation
  • HaydenMSGhoshS2004Signaling to NF-κB. Genes and Development1821952224.

  • HeldringNPikeAAnderssonSMatthewsJChengGHartmanJTujagueMStromATreuterEWarnerM2007Estrogen receptors: how do they signal and what are their targets. Physiological Reviews87905931.

    • Search Google Scholar
    • Export Citation
  • HideshimaTMitsiadesCTononGRichardsonPGAndersonKC2007Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nature Reviews. Cancer7585598.

    • Search Google Scholar
    • Export Citation
  • HolstFStahlPRRuizCHellwinkelOJehanZWendlandMLebeauATerraccianoLAl-KurayaKJanickeF2007Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer. Nature Genetics39655660.

    • Search Google Scholar
    • Export Citation
  • HurJChesnesJCoserKRLeeRSGeckPIsselbacherKJShiodaT2004The Bik BH3-only protein is induced in estrogen-starved and antiestrogen-exposed breast cancer cells and provokes apoptosis. PNAS10123512356.

    • Search Google Scholar
    • Export Citation
  • HurdCKhattreeNDindaSAlbanPMoudgilVK1997Regulation of tumor suppressor proteins, p53 and retinoblastoma, by estrogen and antiestrogens in breast cancer cells. Oncogene15991995.

    • Search Google Scholar
    • Export Citation
  • JamersonMHJohnsonMDDicksonRB2004Of mice and Myc: c-Myc and mammary tumorigenesis. Journal of Mammary Gland Biology and Neoplasia92737.

    • Search Google Scholar
    • Export Citation
  • JanickeRUSprengartMLWatiMRPorterAG1998Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. Journal of Biological Chemistry27393579360.

    • Search Google Scholar
    • Export Citation
  • JordanVC2004Selective estrogen receptor modulation: concept and consequences in cancer. Cancer Cell5207213.

  • JordanVC2007SERMs: meeting the promise of multifunctional medicines. Journal of the National Cancer Institute99350356.

  • JordanVCBrodieAM2007Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer. Steroids72725.

    • Search Google Scholar
    • Export Citation
  • JordanVCLewisJSOsipoCChengD2005The apoptotic action of estrogen following exhaustive antihormonal therapy: a new clinical treatment strategy. Breast14624630.

    • Search Google Scholar
    • Export Citation
  • KalaitzidisDGilmoreTD2005Transcription factor cross-talk: the estrogen receptor and NF-κB. Trends in Endocrinology and Metabolism164652.

    • Search Google Scholar
    • Export Citation
  • KallioAZhengADahllundJHeiskanenKMHarkonenP2005Role of mitochondria in tamoxifen-induced rapid death of MCF-7 breast cancer cells. Apoptosis1013951410.

    • Search Google Scholar
    • Export Citation
  • KandouzMLombetAPerrotJYJacobDCarvajalSKazemARosteneWTherwathAGompelA1999Proapoptotic effects of antiestrogens, progestins and androgen in breast cancer cells. Journal of Steroid Biochemistry and Molecular Biology69463471.

    • Search Google Scholar
    • Export Citation
  • KuiperGGEnmarkEPelto-HuikkoMNilssonSGustafssonJA1996Cloning of a novel receptor expressed in rat prostate and ovary. PNAS9359255930.

  • LeungLKDoLWangTT1998Regulation of death promoter Bak expression by cell density and 17 beta-estradiol in MCF-7 cells. Cancer Letters1244752.

    • Search Google Scholar
    • Export Citation
  • LewisJSMeekeKOsipoCRossEAKidawiNLiTBellEChandelNSJordanVC2005Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation. Journal of the National Cancer Institute9717461759.

    • Search Google Scholar
    • Export Citation
  • LillingGNordenbergJRotterVGoldfingerNPellerSSidiY2002Altered subcellular localization of p53 in estrogen-dependent and estrogen-independent breast cancer cells. Cancer Investigation20509517.

    • Search Google Scholar
    • Export Citation
  • LindbergMKMoverareSSkrticSGaoHDahlamn-WrightKGustafssonJAOhlssonC2003Estrogen receptor (ER)-β reduces ERα-regulated gene transcription, supporting a ‘ying yang’ relationship between ERα and ERβ in mice. Molecular Endocrinology17203208.

    • Search Google Scholar
    • Export Citation
  • LiuMMAlbaneseCAndersonCMHiltyKWebbPUhtRMPriceRH JrPestellRGKushnerPJ2002Opposing action of estrogen receptors alpha and beta on cyclin D1 gene expression. Journal of Biological Chemistry2772435324360.

    • Search Google Scholar
    • Export Citation
  • LiuWKonduriSDBansalSNayakBKRajasekaranSAKaruppayilSMRajasekaranAKDasGM2006Estrogen receptor-alpha binds p53 tumor suppressor protein directly and represses its function. Journal of Biological Chemistry28198379840.

    • Search Google Scholar
    • Export Citation
  • LonardDMO'MalleyBW2007Nuclear receptor coregulators: judges, juries, and executioners of cellular regulation. Molecular Cell27691700.

    • Search Google Scholar
    • Export Citation
  • LuoJManningBDCantleyLC2003Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell4257262.

  • MaillardSAmellerTGauduchonJGougeletAGouilleuxFLegrandPMarsaudVFattalESolaBRenoirJM2005Innovative drug delivery nanosystems improve the anti-tumor activity in vitro and in vivo of anti-estrogens in human breast cancer and multiple myeloma. Journal of Steroid Biochemistry and Molecular Biology94111121.

    • Search Google Scholar
    • Export Citation
  • MaillardSGauduchonJMarsaudVGouilleuxFConnaultEOpolonPFattalESolaBRenoirJM2006Improved antitumoral properties of pure antiestrogen RU 58668-loaded liposomes in multiple myeloma. Journal of Steroid Biochemistry and Molecular Biology1006778.

    • Search Google Scholar
    • Export Citation
  • MandlekarSYuRTanTHKongAN2000Activation of caspase-3 and c-Jun NH2-terminal kinase-1 signaling pathways in tamoxifen-induced apoptosis of human breast cancer cells. Cancer Research6059956000.

    • Search Google Scholar
    • Export Citation
  • MartinLAFarmerIJohnstonSRAliSDowsetM2005Elevated ERK1/ERK2/estrogen receptor cross-talk enhances estrogen-mediated signaling during long-term estrogen deprivation. Endocrine-Related Cancer12S75S84.

    • Search Google Scholar
    • Export Citation
  • MatthewsJWihlenBTujagueMWanJSttromAGustafssonJA2006Estrogen receptor (ER) β modulates ERα-mediated transcriptional activation by altering the recruitment of c-Fos and c-Jun to estrogen-responsive promoters. Molecular Endocrinology20534543.

    • Search Google Scholar
    • Export Citation
  • MedinaKLStrasserAKincadePW2000Estrogen influences the differentiation, proliferation, and survival of early B-lineage precursors. Blood9520592067.

    • Search Google Scholar
    • Export Citation
  • MichalidesRGriekspoorABalkenendeAVerwoerdDJanssenLJalinkKFlooreAVeldsAvan't VeerLNeefjesJ2004Tamoxifen resistance by a conformational arrest of the estrogen receptor alpha after PKA activation in breast cancer. Cancer Cell5597605.

    • Search Google Scholar
    • Export Citation
  • MolinaJMassoFPaezAMendezCRodriguezEMandokiJJDiaz de LeonLMontanoLF1999Differential effect of estradiol on antibody secretion of murine hybridomas. Hybridoma18377383.

    • Search Google Scholar
    • Export Citation
  • MolinariAMBontempoPSchiavoneEMTortoraVVerdiccioMANapolitanoMNolaEMontcharmontBMediciNNigroV2000Estradiol induces functional inactivation of p53 by intracellular redistribution. Cancer Research6025942597.

    • Search Google Scholar
    • Export Citation
  • MossRLGuQWongMEstrogen: nontranscriptional signaling pathway(discussion 68–9)Recent Progress in Hormone Research5219973368.

  • MosselmanSPolmanJDijkemaR1996ER β: identification and characterization of a novel human estrogen receptor. FEBS Letters3924953.

  • MuraokaRSLenferinkAESimpsonJBrantleyDMRoebuckLRYakesFMArteagaCL2001Cyclin-dependent kinase inhibitor p27(Kip1) is required for mouse mammary gland morphogenesis and function. Journal of Cell Biology153917932.

    • Search Google Scholar
    • Export Citation
  • MusgroveEAHamiltonJALeeCSSweeneyKJWattsCKSutherlandRL1993Growth factor, steroid, and steroid antagonist regulation of cyclin gene expression associated with changes in T-47D human breast cancer cell cycle progression. Molecular and Cellular Biology1335773587.

    • Search Google Scholar
    • Export Citation
  • NagarkattiNDavisBA2003Tamoxifen induces apoptosis in Fas+ tumor cells by upregulating the expression of Fas ligand. Cancer Chemotherapy and Pharmacology51284290.

    • Search Google Scholar
    • Export Citation
  • NakshatriHBhat-NakshatriPMartinDAGouletRJ JrSledgeGW Jr1997Constitutive activation of NF-κB during progression of breast cancer to hormone-independent growth. Molecular and Cellular Biology1736293639.

    • Search Google Scholar
    • Export Citation
  • NicholsonRIHutchesonIRBrittonDKnowldenJMJonesHEHarperMEHiscoxSEBarrowDGeeJM2005Growth factor signalling networks in breast cancer and resistance to endocrine agents: new therapeutic strategies. Journal of Steroid Biochemistry and Molecular Biology93257262.

    • Search Google Scholar
    • Export Citation
  • ObreroMYuDVShapiroDJ2002Estrogen receptor-dependent and estrogen receptor-independent pathways for tamoxifen and 4-hydroxytamoxifen-induced programmed cell death. Journal of Biological Chemistry2774569545703.

    • Search Google Scholar
    • Export Citation
  • OlivierSClosePCastermansEde LevalLTabruynSChariotAMalaiseMMervilleMPBoursVFranchimontN2006Raloxifene-induced myeloma cell apoptosis: a study of nuclear factor-κB inhibition and gene expression signature. Molecular Pharmacology6916151623.

    • Search Google Scholar
    • Export Citation
  • O'MalleyBW2005A life-long search for the molecular pathways of steroid hormone action. Molecular Endocrinology1914021411.

  • OsborneCKSchiffR2005Estrogen-receptor biology: continuing progress and therapeutic implications. Journal of Clinical Oncology2316161622.

    • Search Google Scholar
    • Export Citation
  • OtsukiTYamadaOKurebayashiJMoriyaTSakaguchiHKunisieHYataKUnoMYawataYUekiA2000Estrogen receptors in human myeloma cells. Cancer Research6014341441.

    • Search Google Scholar
    • Export Citation
  • Planas-SilvaMDWeinbergRA1997Estrogen-dependent cyclin E-cdk2 activation through p21 redistribution. Molecular and Cellular Biology1740594069.

    • Search Google Scholar
    • Export Citation
  • PopovVMWangCShirleyLARosenbergALiSNevalainenMFuMPestellRG2007The functional significance of nuclear receptor acetylation. Steroids72221230.

    • Search Google Scholar
    • Export Citation
  • PrallOWSarcevicBMusgroveEWattsCKSutherlandRL1997Estrogen-induced activation of Cdk4 and Cdk2 during G1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-Cdk2. Journal of Biological Chemistry2721088210894.

    • Search Google Scholar
    • Export Citation
  • PrallOWRoganEMMusgroveEAWattsCKSutherlandRL1998c-Myc or cyclin D1 mimics estrogen effects on cyclin E-Cdk2 activation and cell cycle reentry. Molecular and Cellular Biology1844994508.

    • Search Google Scholar
    • Export Citation
  • PrallOWCarrollJSSutherlandRL2001A low abundance pool of nascent p21WAF1/Cip1 is targeted by estrogen to activate cyclin E*Cdk2. Journal of Biological Chemistry2764543345442.

    • Search Google Scholar
    • Export Citation
  • PrattMABishopTEWhiteDYasvinskiGMenardMNiuNYClarkeR2003Estrogen withdrawal-induced NF-κB activity and bcl-3 expression in breast cancer cells: roles in growth and hormone independence. Molecular and Cellular Biology2368876900.

    • Search Google Scholar
    • Export Citation
  • RayAPrefontaineKERayP1994Down-modulation of interleukin-6 gene expression by 17 beta-estradiol in the absence of high affinity DNA binding by the estrogen receptor. Journal of Biological Chemistry2691294012946.

    • Search Google Scholar
    • Export Citation
  • RenoirJMStellaBAmellerTConnaultEOpolonPMarsaudV2006Improved anti-tumoral capacity of mixed and pure anti-oestrogens in breast cancer cell xenografts after their administration by entrapment in colloidal nanosystems. Journal of Steroid Biochemistry and Molecular Biology102114127.

    • Search Google Scholar
    • Export Citation
  • RigginsRBBoutonAHLiuMCClarkeR2005aAntiestrogens, aromatase inhibitors, and apoptosis in breast cancer. Vitamins and Hormones71201237.

    • Search Google Scholar
    • Export Citation
  • RigginsRBZwartANehraRClarkeR2005bThe nuclear factor kappa B inhibitor parthenolide restores ICI 182,780 (Faslodex; fulvestrant)-induced apoptosis in antiestrogen-resistant breast cancer cells. Molecular Cancer Therapeutics43341.

    • Search Google Scholar
    • Export Citation
  • SabbahMCourilleauDMesterJRedeuilhG1999Estrogen induction of the cyclin D1 promoter: involvement of a cAMP response-like element. PNAS961121711222.

    • Search Google Scholar
    • Export Citation
  • SayeedAKonduriSDLiuWBansalSLiFDasGM2007Estrogen receptor alpha inhibits p53-mediated transcriptional repression: implications for the regulation of apoptosis. Cancer Research6777467755.

    • Search Google Scholar
    • Export Citation
  • SherrCJRobertsJM1999CDK inhibitors: positive and negative regulators of G1-phase progression. Genes and Development1315011512.

  • ShimGJWangLAnderssonSNagyNKisLLZhangQMakelaSWarnerMGustafssonJA2003Disruption of the estrogen receptor beta gene in mice causes myeloproliferative disease resembling chronic myeloid leukemia with lymphoid blast crisis. PNAS10066946699.

    • Search Google Scholar
    • Export Citation
  • ShimGJGhermanDKimHJOmotoYIwaseHBoutonDKisLLAnderssonCTWarnerMGustafssonJA2006Differential expression of oestrogen receptors in human secondary lymphoid tissues. Journal of Pathology208408414.

    • Search Google Scholar
    • Export Citation
  • SlingerlandJPaganoM2000Regulation of the cdk inhibitor p27 and its deregulation in cancer. Journal of Cellular Physiology1831017.

  • SmithsonGCouseJFLubahnDBKorachKSKincadePW1998The role of estrogen receptors and androgen receptors in sex steroid regulation of B lymphopoiesis. Journal of Immunology1612734.

    • Search Google Scholar
    • Export Citation
  • SmolnikarKLoffekSSchulzTMichnaHDielP2000Treatment with the pure antiestrogen faslodex (ICI 182780) induces tumor necrosis factor receptor 1 (TNFR1) expression in MCF-7 breast cancer cells. Breast Cancer Research and Treatment63249259.

    • Search Google Scholar
    • Export Citation
  • SolaBRenoirJM2006Antiestrogenic therapies in solid cancers and multiple myeloma. Current Molecular Medicine6359368.

  • SolaBRenoirJM2007Estrogenic or antiestrogenic therapies for multiple myeloma?Molecular Cancer659

  • SomaiSChaouatMJacobDPerrotJYRosteneWForgezPGompelA2003Antiestrogens are pro-apoptotic in normal human breast epithelial cells. International Journal of Cancer105607612.

    • Search Google Scholar
    • Export Citation
  • SongRXSantenRJ2003Apoptotic action of estrogen. Apoptosis85560.

  • SongRXFanPYueWChenYSantanRJRole of receptor complexes in the extranuclear actions of estrogen receptor alpha in breast cancerEndocrine-Related Cancer13Suppl 12006S3S13.

    • Search Google Scholar
    • Export Citation
  • StrasserAO'ConnorLDixitVM2000Apoptosis signaling. Annual Review of Biochemistry69217245.

  • StromAHartmanJFosterJSKietzSWimalasenaJGustafssonJA2004Estrogen receptor beta inhibits 17β-estradiol-stimulated proliferation of the breast cancer cell line T47D. PNAS10115661571.

    • Search Google Scholar
    • Export Citation
  • SunMPacigaJEFeldmanRIYuanZCoppolaDLuYYShelleySANicosiaSVChengJQ2001Phosphatidylinositol-3-OH Kinase (PI3K)/AKT2, activated in breast cancer, regulates and is induced by estrogen receptor alpha (ERα) via interaction between ERα and PI3K. Cancer Research6159855991.

    • Search Google Scholar
    • Export Citation
  • ThiantanawatALongBJBrodieAM2003Signaling pathways of apoptosis activated by aromatase inhibitors and antiestrogens. Cancer Research6380378050.

    • Search Google Scholar
    • Export Citation
  • TreonSPTeohGUrashimaMOgataAChauhanDWebbIJAndersonKC1998Anti-estrogens induce apoptosis of multiple myeloma cells. Blood9217491757.

  • TsaiEMWangSCLeeJNHungMC2001Akt activation by estrogen in estrogen receptor-negative breast cancer cells. Cancer Research6183908392.

  • WatsonPHPonRTShiuRP1991Inhibition of c-myc expression by phosphorothioate antisense oligonucleotide identifies a critical role for c-myc in the growth of human breast cancer. Cancer Research5139964000.

    • Search Google Scholar
    • Export Citation
  • WattsCKBradyASarcevicBDeFazioAMusgroveEASutherlandRL1995Antiestrogen inhibition of cell cycle progression in breast cancer cells in associated with inhibition of cyclin-dependent kinase activity and decreased retinoblastoma protein phosphorylation. Molecular Endocrinology918041813.